EP1037912A1 - DNA MOLECULES ENCODING VERTEBRATE NUCLEAR RECEPTOR PROTEIN, nNR4 - Google Patents
DNA MOLECULES ENCODING VERTEBRATE NUCLEAR RECEPTOR PROTEIN, nNR4Info
- Publication number
- EP1037912A1 EP1037912A1 EP98963116A EP98963116A EP1037912A1 EP 1037912 A1 EP1037912 A1 EP 1037912A1 EP 98963116 A EP98963116 A EP 98963116A EP 98963116 A EP98963116 A EP 98963116A EP 1037912 A1 EP1037912 A1 EP 1037912A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nnr4
- protein
- expression vector
- host cell
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108020004017 nuclear receptors Proteins 0.000 title abstract description 44
- 108020005497 Nuclear hormone receptor Proteins 0.000 title description 32
- 241000251539 Vertebrata <Metazoa> Species 0.000 title description 9
- 102000007399 Nuclear hormone receptor Human genes 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 110
- 102000004169 proteins and genes Human genes 0.000 claims description 101
- 108020004414 DNA Proteins 0.000 claims description 66
- 239000013604 expression vector Substances 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 23
- 102000053602 DNA Human genes 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 abstract description 68
- 102000006255 nuclear receptors Human genes 0.000 abstract description 43
- 239000013598 vector Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 238000012216 screening Methods 0.000 abstract description 12
- 241000282414 Homo sapiens Species 0.000 abstract description 9
- 238000002955 isolation Methods 0.000 abstract description 4
- 238000012512 characterization method Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 69
- 108020004635 Complementary DNA Proteins 0.000 description 68
- 238000010804 cDNA synthesis Methods 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 57
- 150000007523 nucleic acids Chemical class 0.000 description 33
- 239000012634 fragment Substances 0.000 description 32
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 108020004705 Codon Proteins 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 17
- 108091033319 polynucleotide Proteins 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 15
- 239000013615 primer Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000004927 fusion Effects 0.000 description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108020001756 ligand binding domains Proteins 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 230000003053 immunization Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 241000238631 Hexapoda Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 108091033380 Coding strand Proteins 0.000 description 7
- 230000004568 DNA-binding Effects 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108091060211 Expressed sequence tag Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000011712 cell development Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108091005461 Nucleic proteins Chemical group 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 108091008039 hormone receptors Proteins 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101150066516 GST gene Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- -1 nNR4 Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 102000005969 steroid hormone receptors Human genes 0.000 description 2
- 108020003113 steroid hormone receptors Proteins 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Norphytane Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 150000001945 cysteines Chemical group 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates in part to isolated nucleic acid molecules (polynucleotide) which encode a mouse nuclear receptor protein, referred to throughout as nNR4.
- the present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding nNR4, substantially purified forms of associated nNR4 protein, mutant proteins, and methods associated with identifying compounds which modulate nNR4 activity.
- the nuclear receptor superfamily which includes steroid hormone receptors, are small chemical ligand-inducible transcription factors which have been shown to play roles in controlling development, differentiation and physiological function. Isolation of cDNA clones encoding nuclear receptors reveal several characteristics. First, the NH2-terminal regions, which vary in length between receptors, is hypervariable with low homology between family members. There are three internal regions of conservation, referred to as domain I, II and III. Region I is a cysteine-rich region which is referred to as the DNA binding domain (DBD). Regions II and III are within the COOH-terminal region of the protein and is also referred to as the ligand binding domain (LBD). For a review, see Power et al. (1992, Trends in Pharmaceutical Sciences 13: 318-323).
- a nucleic acid molecule expressing a nuclear receptor protein will be useful in screening for compounds acting as a modulator of cell differentiation, cell development and physiological function.
- the present invention addresses and meets these needs by disclosing isolated nucleic acid molecules which express a nuclear receptor protein which will have a role in cell differentiation and development.
- the present invention relates to isolated nucleic acid molecules (polynucleotides) which encode novel nuclear receptor proteins which are herein designated as members of the nuclear receptor superfamily.
- the isolated polynucleotides of the present invention encode vertebrate members of this nuclear receptor superfamily, and preferably an isolated polynucleotide encoding a murine nuclear receptor protein, such as a nuclear receptor protein exemplified and referred to throughout this specification as nNR4.
- the nuclear receptor proteins encoded by the isolated polynucleotides of the present invention are involved in the regulation of in vivo cell proliferation and/or cell development.
- nNR4 nuclear receptor proteins encoded by isolated polynucleotides of the present invention are involved in the regulation of gene expression, expressed in substantial quantity in the liver and show structural similarity to another member of the nuclear receptor superfamily, the vitamin D receptor.
- the nuclear receptor proteins encoded by the isolated polynucleotides of the present invention are involved in the regulation of gene expression.
- nNR4 is mainly expressed in mouse liver at high level, and the most related nuclear receptor with known function is vitamin D receptor, it is likely that nNR4 plays important roles in metabolism and the endogenous ligand regulating nNR4 may very likely to be a metabolic intermediate.
- the present invention also relates to isolated nucleic acid fragments which encode mRNA expressing a biologically active novel vertebrate nuclear receptor which belongs to the nuclear receptor superfamily.
- a preferred embodiment relates to isolated nucleic acid fragments of SEQ ID NO: 1 which encode mRNA expressing a biologically functional derivative of nNR4. Any such nucleic acid fragment will encode either a protein or protein fragment comprising at least an intracellular DNA-binding domain and/or ligand binding domain, domains conserved throughout the nuclear receptor family domain which exist in nNR4 (SEQ ID NO: 2).
- any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy- terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists of nNR4.
- the isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
- DNA deoxyribonucleic acid molecule
- cDNA complementary DNA
- synthetic DNA such as a synthesized, single stranded polynucleotide.
- the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
- the present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.
- recombinant vectors and recombinant hosts both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.
- a preferred aspect of the present invention is disclosed in
- Figure 1A-B and SEQ ID NO: 1 an isolated cDNA encoding a novel nuclear trans-acting receptor protein, nNR4.
- nNR4 novel nuclear trans-acting receptor protein
- the present invention also relates to biologically functional derivatives of nNR4 as set forth as SEQ ID NO: 2, including but not limited to nNR4 mutants and biologically active fragments such as amino acid substitutions, deletions, additions, amino terminal truncations and carboxy- terminal truncations, such that these fragments provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and which would be useful for screening for agonists and/or antagonists of nNR4 function.
- the present invention also relates to polyclonal and monoclonal antibodies raised in response to either form of nNR4 disclosed herein, or a biologically functional derivative thereof. It will be especially preferable to raise antibodies against epitopes within the NH2-terminal domain of nNR4, which show the least homology to other known proteins belonging to the nuclear receptor superfamily.
- the DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of nNR4.
- the recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of nNR4.
- the present invention also relates to isolated nucleic acid molecules which are fusion constructions expressing fusion proteins useful in assays to identify compounds which modulate wild-type nNR4 activity.
- a preferred aspect of this portion of the invention includes, but is not limited to, glutathione S-transferase GST-nNR4 fusion constructs. These fusion constructs include, but are not limited to, all or a portion of the ligand-binding domain of nNR4, respectively, as an in-frame fusion at the carboxy terminus of the GST gene.
- the disclosure of SEQ ID Nos: 1-2 allow the artisan of ordinary skill to construct any such nucleic acid molecule encoding a GST-nuclear receptor fusion protein.
- Soluble recombinant GST-nuclear receptor fusion proteins may be expressed in various expression systems, including Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (e.g., Bac- N-Blue DNA from Invitrogen or pAcG2T from Pharmingen). It is an object of the present invention to provide an isolated polynucleotide as set forth in SEQ ID NO: 1.
- a nuclear receptor protein such as nNR4, nuclear receptor protein fragments of full length proteins such as nNR4, and mutants which are derivatives of SEQ ID NO: 2.
- Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for nNR4 function.
- Another object of this invention is tissue typing using probes or antibodies of this invention.
- polynucleotide probes are used to identify tissues expressing nNR4 mRNA.
- probes or antibodies can be used to identify a type of tissue based on nNR4 expression or display of nNR4 receptors.
- DBD refers to DNA binding domain.
- LBD refers to ligand binding domain
- mamalian host refers to any mammal, including a human being.
- Figure 1A-B show the nucleotide sequence (SEQ ID NO: 1) which comprises the open reading frame encoding the nuclear receptor protein, nNR4.
- Figure 2A-B show the coding strand of the isolated cDNA molecule (SEQ ID NO: 1) which encodes nNR4, and the amino acid sequence (SEQ ID NO: 2) of nNR4. The region in bold is the DNA binding domain.
- Figure 3 shows the amino acid sequence (SEQ ID NO: 2) of nNR4. The region in bold is the DNA binding domain.
- the present invention relates to isolated nucleic acid and protein forms which represent vertebrate nuclear receptors. These expressed proteins are novel nuclear receptors which are useful in the identification of downstream target genes and ligands regulating their activity.
- the nuclear receptor proteins encoded by the isolated polynucleotides of the present invention are involved in the regulation of in vivo cell proliferation and/or cell development.
- the nuclear receptor superfamily is composed of a group of structurally related receptors which are regulated by chemically distinct ligands.
- the common structure for a nuclear receptor is a highly conserved DNA binding domain (DBD) located in the center of the peptide and the ligand-binding domain (LBD) at the COOH-terminus.
- DBD DNA binding domain
- LBD ligand-binding domain
- the DBDs share at least 50% to 60% amino acid sequence identity even among the most distant members in vertebrates.
- the superfamily has been expanded within the past decade to contain approximately 25 subfamilies.
- EST clones corresponding to GenBank Ass. #'s AA106163 and AA396982 were obtained from Genome Systems Inc. (St. Louis, Missouri, http://www. genomesysytems.com).
- the cDNA clone AA106163 is also identified as Image Consortium ID No. 521858 and dbEST ID No. 743956 while the cDNA clone AA396982 is also identified as Image Consortium ID No.
- PCR nested primer analysis was utilized to scan a mouse brain cDNA library.
- a PCR fragment of with expected size (approximately 350 bps) was amplified from mouse brain cDNA and the DNA fragment was purified using Qiagen gel extraction kit and subjected to automated sequencing. The sequence information showed a complete DBD region.
- the full length cDNA clone for nNR4 was obtained via PCR using a 5'-end primer and a 3'-end primer on mouse brain cDNA, mouse embryo cDNA (Clontech, Palo Alto, CA, USA) and mouse testis cDNA (Clontech, Palo Alto, CA, USA).
- a 1.2 kb DNA fragment from mouse embryo cDNA was cloned into the pCRII vector (Invitrogen, San Diego, CA) and multiple clones were sequenced to identify the clone coding wild type protein sequence.
- the present invention also relates to isolated nucleic acid fragments of nNR4 (SEQ ID NO: 1) which encode mRNA expressing a biologically active novel nuclear receptor. Any such nucleic acid fragment will encode either a protein or protein fragment comprising at least an intracellular DNA-binding domain and/or ligand binding domain, domains conserved throughout the nuclear receptor family domain which exist in nNR4 (SEQ ID NO: 2).
- any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these biologically functional derivatives encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for nNR4 function.
- the isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
- DNA deoxyribonucleic acid molecule
- cDNA complementary DNA
- synthetic DNA such as a synthesized, single stranded polynucleotide.
- the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
- the present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.
- FIG. 1A-B A preferred aspect of the present invention is disclosed in Figure 1A-B and SEQ ID NO: 1, a cDNA encoding a novel nuclear trans- acting receptor protein, nNR4, disclosed as follows:
- the present invention also relates to a substantially purified form of the novel nuclear trans-acting receptor protein, nNR4, which is shown in Figures 2A-B and Figure 3 and as set forth in SEQ ID NO: 2, disclosed as follows:
- the present invention also relates to biologically functional derivatives and/or mutants of nNR4 as set forth as SEQ ID NO: 2, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists of nNR4 function.
- the present invention also relates to isolated nucleic acid molecules which are fusion constructions expressing fusion proteins useful in assays to identify compounds which modulate wild-type nNR4 activity.
- a preferred aspect of this portion of the invention includes, but is not limited to, glutathione S-transferase GST-nNR4 and/or GST-nNR4 fusion constructs.
- These fusion constructs include, but are not limited to, all or a portion of the ligand-binding domain of nNR4, respectively, as an in-frame fusion at the carboxy terminus of the GST gene.
- the disclosure of SEQ ID NOS: 1-2 allow the artisan of ordinary skill to construct any such nucleic acid molecule encoding a GST-nuclear receptor fusion protein.
- Soluble recombinant GST-nuclear receptor fusion proteins may be expressed in various expression systems, including Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (e.g., Bac-N-Blue DNA from Invitrogen or pAcG2T from Pharmingen).
- Spodoptera frugiperda Sf21 insect cells
- baculovirus expression vector e.g., Bac-N-Blue DNA from Invitrogen or pAcG2T from Pharmingen.
- the isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
- DNA deoxyribonucleic acid molecule
- cDNA complementary DNA
- synthetic DNA such as a synthesized, single stranded polynucleotide.
- the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
- this invention is also directed to those DNA sequences encode RNA comprising alternative codons which code for the eventual translation of the identical amino acid, as shown below:
- the present invention discloses codon redundancy which may result in differing DNA molecules expressing an identical protein.
- a sequence bearing one or more replaced codons will be defined as a degenerate variation.
- mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.
- DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally occurring peptide.
- Methods of altering the DNA sequences include but are not limited to site directed mutagenesis.
- altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a receptor for a ligand.
- nucleic acid, protein, or respective fragment thereof in question has been substantially removed from its in vivo environment so that it may be manipulated by the skilled artisan, such as but not limited to nucleotide sequencing, restriction digestion, site-directed mutagenesis, and subcloning into expression vectors for a nucleic acid fragment as well as obtaining the protein or protein fragment in pure quantities so as to afford the opportunity to generate polyclonal antibodies, monoclonal antibodies, amino acid sequencing, and peptide digestion. Therefore, the nucleic acids claimed herein may be present in whole cells or in cell lysates or in a partially purified or substantially purified form.
- a nucleic acid is considered substantially purified when it is purified away from environmental contaminants.
- a nucleic acid sequence isolated from cells is considered to be substantially purified when purified from cellular components by standard methods while a chemically synthesized nucleic acid sequence is considered to be substantially purified when purified from its chemical precursors.
- the present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.
- the present invention also relates to methods of expressing nNR4 and biological equivalents disclosed herein, assays employing these recombinantly expressed gene products, cells expressing these gene products, and agonistic and/or antagonistic compounds identified through the use of assays utilizing these recombinant forms, including, but not limited to, one or more modulators of the nNR4 either through direct contact with the LBD or through direct or indirect contact with a ligand which either interacts with the DBD or with the wild-type transcription complex which nNR4 interacts in trans, thereby modulating cell differentiation or cell development.
- a "biologically functional derivative" of a wild-type nNR4 possesses a biological activity that is related to the biological activity of the wild type nNR4.
- the term “functional derivative” is intended to include “fragments,” “mutants,” “variants,” “degenerate variants,” “analogs” and “homologues” of the wild type nNR4 protein.
- fragment is meant to refer to any polypeptide subset of wild-type nNR4, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations.
- mutant is meant to refer a subset of a biologically active fragment that may be substantially similar to the wild-type form but possesses distinguishing biological characteristics. Such altered characteristics include but are in no way limited to altered substrate binding, altered substrate affinity and altered sensitivity to chemical compounds affecting biological activity of the nNR4 or nNR4 functional derivative.
- variant is meant to refer to a molecule substantially similar in structure and function to either the entire wild-type protein or to a fragment thereof. A molecule is "substantially similar" to a wild-type nNR4-like protein if both molecules have substantially similar structures or if both molecules possess similar biological activity.
- analog refers to a molecule substantially similar in function to either the full-length nNR4 protein or to a biologically functional derivative thereof.
- nNR4 any of a variety of procedures may be used to clone nNR4. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, Proc. Natl. Acad. Sci. USA 85: 8998- 9002). 5' and/or 3' RACE may be performed to generate a full-length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of nNR4 cDNA.
- These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the nNR4 cDNA following the construction of a nNR4-containing cDNA library in an appropriate expression vector system; (3) screening a nNR4- containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the nNR4 protein; (4) screening a nNR4-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the nNR4 protein.
- EST expressed sequence tag
- This partial cDNA is obtained by the specific PCR amplification of nNR4 DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other kinases which are related to the nNR4 protein; (5) screening a nNR4-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the nNR4 protein.
- This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of nNR4 cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using SEQ ID NO: 1 as a template so that either the full-length cDNA may be generated by known PCR techniques, or a portion of the coding region may be generated by these same known PCR techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full-length version of the nucleotide sequence encoding nNR4.
- libraries as well as libraries constructed from other cell types-or species types, may be useful for isolating a nNR4-encoding DNA or a nNR4 homologue.
- Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines other than cells or tissue such as human cells, rodent cells or any other such vertebrate host which may contain a homologue of nNR4.
- a nNR4 gene and homologues may be isolated by oligonucleotide- or polynucleotide-based hybridization screening of a vertebrate genomic library, including but not limited to, a human genomic library and a rodent genomic library.
- cDNA libraries may be prepared from cells or cell lines which have nNR4 activity.
- the selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding nNR4 may be done by first measuring cell-associated nNR4 activity using any known assay available for such a purpose.
- cDNA libraries can be performed by standard techniques well known in the art.
- Well known cDNA library construction techniques can be found for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
- Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene. It is also readily apparent to those skilled in the art that DNA encoding nNR4 may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in Sambrook, et al., supra.
- the amino add sequence or DNA sequence of nNR4 or a homologous protein may be necessary.
- the nNR4 protein or a homologous protein may be purified and partial amino add sequence determined by automated sequenators. It is not necessary to determine the entire amino add sequence, but the linear sequence of two regions of 6 to 8 amino adds can be determined for the PCR amplification of a partial nNR4 DNA fragment. Once suitable amino add sequences have been identified, the DNA sequences capable of encoding them are synthesized.
- the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the nNR4 sequence but others in the set will be capable of hybridizing to nNR4 DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still suffidently hybridize to the nNR4 DNA to permit identification and isolation of nNR4 encoding DNA.
- the nucleotide sequence of a region of an expressed sequence may be identified by searching one or more available genomic databases.
- Gene-specific primers may be used to perform PCR amplification of a cDNA of interest from either a cDNA library or a population of cDNAs.
- the appropriate nucleotide sequence for use in a PCR-based method may be obtained from SEQ ID NO: 1, either for the purpose of isolating overlapping 5' and 3' RACE products for generation of a full-length sequence coding for nNR4, or to isolate a portion of the nucleotide sequence coding for nNR4 for use as a probe to screen one or more cDNA- or genomic-based libraries to isolate a full-length sequence encoding nNR4 or nNR4-like proteins.
- the nNR4 full-length cDNA of the present invention were generated by confirmation of DNA sequence analysis of 5' and 3' ESTs from mouse and PCR-based cloning of a missing portion of the coding region.
- a full length cDNA clone for nNR4 was obtained via PCR using a 5'-end primer and a 3 '-end primer on mouse brain cDNA, mouse embryo cDNA and mouse testis cDNA.
- a 1.2 kb DNA fragment from mouse embryo cDNA was cloned into plasmid pCRII (Invitrogen, San Diego, CA) and multiple clones were sequenced, which resulted in the identification of the mouse nNR4 clone.
- the mouse nNR4 cDNA encodes a peptide of 357 amino adds, which has the distinctive DBD and LBD structures. It is most related to human orphan nuclear hormone receptor (hONR) and shares 75% a.a. sequence identity in the overlapping peptide region (Baes et al.,1994,
- nNR4 does not seem to be a mouse homolog of hONR as the two receptors have 10 different amino acids in the most conserved DBD region while homologs usually have almost identical DBD. Thus, nNR4 most likely represents a subtype of this orphan subfamily. nNR4 is highly expressed in liver but not in other tissue as detected through northern analysis.
- a variety of mammalian expression vectors may be used to express recombinant nNR4 in mammalian cells.
- Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their mRNAs in an appropriate host.
- Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, blue green algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria- animal cells.
- An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters.
- a promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis.
- a strong promoter is one which causes mRNAs to be initiated at high frequency.
- Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses.
- mammalian expression vectors which may be suitable for recombinant nNR4 expression, include but are not limited to, pcDNA3.1 (Invitrogen), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Bioloabs), pcDNAI, pcDNAIamp (Invitrogen), pcDNA3 (Invitrogen), pMClneo (Stratagene), pXTl (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-l(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and 1ZD35 (ATCC 37565
- bacterial expression vectors may be used to express recombinant nNR4 in bacterial cells.
- Commercially available bacterial expression vectors which may be suitable for recombinant nNR4 expression include, but are not limited to pQE (Qiagen), pETlla (Novagen), lambda gtll (Invitrogen), and pKK223-3 (Pharmada).
- fungal cell expression vectors may be used to express recombinant nNR4 in fungal cells.
- Commercially available fungal cell expression vectors which may be suitable for recombinant nNR4 expression include but are not limited to pYES2 (Invitrogen) and Pichia expression vector (Invitrogen).
- insect cell expression vectors may be used to express recombinant receptor in insect cells.
- Commercially available insect cell expression vectors which may be suitable for recombinant expression of nNR4 include but are not limited to pBlueBacIII and pBlueBacHis2 (Invitrogen), and pAcG2T (Pharmingen).
- An expression vector containing DNA encoding a nNR4- like protein may be used for expression of nNR4 in a recombinant host cell.
- Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as E. coli, fungal cells such as yeast, mammalian cells including but not limited to cell lines of , bovine, pordne, monkey and rodent origin, and insect cells including but not limited to Drosophila- and silkworm-derived cell lines.
- L cells L-M(TK") ATCC CCL 1.3
- L cells L-M ATCC CCL 1.2
- Saos-2 ATCC HTB-85
- 293 ATCC CRL 1573
- Raji ATCC CCL 86
- CV-1 ATCC CCL 70
- COS-1 ATCC CRL 1650
- COS-7 ATCC CRL 1651
- CHO-K1 ATCC CCL 61
- 3T3 ATCC CCL 92
- NIH/3T3 ATCC CRL 1658
- HeLa ATCC CCL 2
- C127I ATCC CRL 1616
- BS-C-1 ATCC CCL 26
- MRC-5 ATCC CCL 171
- CPAE ATCC CCL 209
- the expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation.
- the expression vector-containing cells are individually analyzed to determine whether they produce nNR4 protein. Identification of nNR4 expressing cells may be done by several means, including but not limited to immunological reactivity with anti-nNR4 antibodies, labeled ligand binding and the presence of host cell-associated nNR4 activity.
- nNR4 cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector (such as pcDNA3.1, pQE, pBlueBacHis2 and pLITMUS28) containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant nNR4.
- an expression vector such as pcDNA3.1, pQE, pBlueBacHis2 and pLITMUS28
- Techniques for such manipulations can be found described in Sambrook, et al., supra , are discussed at length in the Example section and are well known and easily available to the artisan of ordinary skill in the art.
- Expression of nNR4 DNA may also be performed using in vitro produced synthetic mRNA.
- Synthetic mRNA can be effidently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.
- nNR4 cDNA molecules including but not limited to the following can be constructed: a cDNA fragment containing the full- length open reading frame for nNR4 as well as various constructs containing portions of the cDNA encoding only spedfic domains of the protein or rearranged domains of the protein. All constructs can be designed to contain none, all or portions of the 5' and/or 3' untranslated region of a nNR4 cDNA. The expression levels and activity of nNR4 can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells.
- this nNR4 cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells.
- expression vectors including recombinant viruses
- the present invention also relates to polyclonal and monoclonal antibodies raised in response to either the human form of nNR4 disclosed herein, or a biologically functional derivative thereof. It will be espedally preferable to raise antibodies against epitopes within the NH2-te ⁇ ninal domain of nNR4, which show the least homology to other known proteins belonging to the human nuclear receptor superfamily.
- Recombinant nNR4 protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies spedfic for full-length nNR4 protein, or polypeptide fragments of nNR4 protein. Additionally, polyclonal or monoclonal antibodies may be raised against a synthetic peptide (usually from about 9 to about 25 amino adds in length) from a portion of the protein as disclosed in SEQ ID NO: 2. Monosperific antibodies to nNR4 are purified from mammalian antisera containing antibodies reactive against nNR4 or are prepared as monoclonal antibodies reactive with nNR4 using the technique of Kohler and Milstein (1975, Nature 256: 495-497).
- Monosperific antibody as used herein is defined as a single antibody spedes or multiple antibody species with homogenous binding characteristics for nNR4.
- Homogenous binding as used herein refers to the ability of the antibody species to bind to a spedfic antigen or epitope, such as those assodated with nNR4, as described above.
- nNR4-spedfic antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of nNR4 protein or a synthetic peptide generated from a portion of nNR4 with or without an immune adjuvant.
- Preimmune serum is collected prior to the first immunization.
- Each animal receives between about 0.1 mg and about 1000 mg of nNR4 protein associated with an acceptable immune adjuvant.
- acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA.
- the initial immunization consists of nNR4 protein or peptide fragment thereof in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both.
- SC subcutaneously
- IP intraperitoneally
- Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization.
- nNR4 in Freund's incomplete adjuvant
- Booster injections are given at about three week intervals until maximal titers are obtained.
- the animals are bled, the serum collected, and aliquots are stored at about -20°C.
- Monoclonal antibodies (mAb) reactive with nNR4 are prepared by immunizing inbred mice, preferably Balb/c, with nNR4 protein.
- the mice are immunized by the IP or SC route with about 1 mg to about 100 mg, preferably about 10 mg, of nNR4 protein in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred.
- the mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 mg of nNR4 in a buffer solution such as phosphate buffered saline by the intravenous (IV) route.
- IV intravenous
- Lymphocytes from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art.
- Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NSl/Ag 4-1, MPC-11, S-194 and Sp 2/0, with Sp 2/0 being preferred.
- the antibody produdng cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%.
- Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected form growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using nNR4 as the antigen. The culture fluids are also tested in the Ouchterlony predpitation assay to determine the isotype of the mAb.
- SPIRA solid phase immunoradioassay
- Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, 1973, Soft Agar Techniques, in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press.
- Monoclonal antibodies are produced in vivo by injection of pristine primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x 106 to about 6 x 106 hybridoma cells about 4 days after priming. Asdtes fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.
- In vitro production of anti-nNR4 mAb is carried out by growing the hybridoma in DMEM containing about 2% fetal calf serum to obtain suffirient quantities of the spedfic mAb.
- the mAb are purified by techniques known in the art.
- Antibody titers of asdtes or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, predpitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of nNR4 in body fluids or tissue and cell extracts.
- Mouse nNR4 antibody affinity columns are made, for example, by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine HCl (pH 8.0). The column is washed with water followed by 0.23 M glydne HCl (pH 2.6) to remove any non-conjugated antibody or extraneous protein.
- the column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supematants or cell extracts containing full-length nNR4 or nNR4 protein fragments are slowly passed through the column.
- the column is then washed with phosphate buffered saline until the optical density (A280) falls to background, then the protein is eluted with 0.23 M glycine-HCl (pH 2.6).
- the purified nNR4 protein is then dialyzed against phosphate buffered saline.
- nNR4-spedfic affinity beads or nNR4-spedfic antibodies are used to isolate 35S-methionine labeled or unlabelled nNR4. Labeled nNR4 protein is analyzed by SDS-PAGE. Unlabelled nNR4 protein is detected by Western blotting, ELISA or RIA assays employing either nNR4 protein spedfic antibodies and/or antiphosphotyrosine antibodies.
- nNR4 protein may be recovered to provide nNR4 protein in active form.
- nNR4 protein purification procedures are available and suitable for use.
- Recombinant nNR4 protein may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography.
- the present invention is also directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding a nNR4 protein.
- Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules.
- Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding nNR4, or the function of nNR4.
- Compounds that modulate the expression of DNA or RNA encoding nNR4 or the biological function thereof may be detected by a variety of assays.
- the assay may be a simple "yes/no" assay to determine whether there is a change in expression or function.
- the assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample.
- Kits containing nNR4, antibodies to nNR4, or modified nNR4 may be prepared by known methods for such uses.
- the DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of nNR4.
- the recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of nNR4.
- Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container.
- the carrier would further comprise reagents such as recombinant nNR4 or anti-nNR4 antibodies suitable for detecting nNR4.
- the carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.
- Pharmaceutically useful compositions comprising modulators of nNR4 may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein, DNA, RNA, modified nNR4, or either nNR4 agonsits or antagonists.
- compositions of the invention are administered to an individual in amounts suffident to treat or diagnose disorders.
- the effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
- the pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.
- chemical derivative describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxidty of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.
- compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration.
- the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection.
- they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
- compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
- compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- the active agents can be administered concurrently, or they each can be administered at separately staggered times.
- the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, spedes, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular compound thereof employed.
- a physirian or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
- Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxidty requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
- AA396982 were obtained from Genome Systems Inc. (St. Louis, Missouri, http://www. genomesysytems.com).
- the cDNA clone AA106163 is also identified as Image
- TTCTGTCTTC AAACAGAGAA TTTCTTCTGT GGGCCTCTTT GCTACAAGAT GGAGGACGCA GTCATGGGTT CCAGTACGAG TTTTTGGAGT CGATCCTCCA CTTCCATAA AACCTGAAAG GACTGCATCT CCAGGAGCCT GAGTATGTGC TCATGGCTGC CACGGCCCTC TTCTCCCCTG ACAGACCCGG AGTTACCCAA AGAGAAGAGA TAGATCAGCT ACAAGAGGAG ATGGCGCTGA TTCTGAACAA CCACATTATG GAACAACAGT CTCGGCTCCA AAGTCGGTTT CTGTATGCAA AGCTGATGGG CCTGCTGGCT GACCTCCGGA GTATAAACAA TGCATACTCC TATGAACTTC AGCGCTTGGA GGAACTGTCT GCTATGACGC CGCTGCTCGG GGAGATTTGC AGTTGAGGCC CAGGCTTGCA TCAGATGGCT GACCTCCGGA GTATAAACAA TGCATACTCC TATGAACT
- PCR primers R6R2 (5'-TCTGGACCAGTTCTTTCTG-3'; SEQ ID NO: 5) and R6F2 (5'-CCATGGCCAGTGAAGAAGAA-3'; SEQ ID NO: 6) flanking the missing exon were designed to scan mouse brain cDNA and a mouse brain cDNA library which was distributed in 96- well plate.
- a PCR fragment of with expected size (approximately 350 bps) was amplified from mouse brain cDNA. The DNA fragment was purified using Qiagen gel extraction kit (QIAGEN, Santa Clarita, CA) and submitted for automated sequencing with primers R6R2 and R6F3
- the sequence information showed a complete DBD region.
- the full length cDNA clone for nNR4 was obtained via PCR using the very 5'-end primer R6F5 (5'-ATTCCTGGCAGTTCCTGAGA-3'; SEQ ID NO: 8) and the very 3'-end primer R6R4 9 (5'-TCCAGGCCAGTGTATCCCTG-3'; SEQ ID NO: 9) on mouse (Mus musculus) brain cDNA, mouse (Mus musculus) embryo cDNA (Clontech, Palo Alto, CA, USA) and mouse (Mus musculus) testis cDNA (Clontech, Palo Alto, CA, USA).
- a 1.2 kb DNA fragment from mouse embryo cDNA was cloned into the pCRII vector (Invitrogen, San Diego, CA) and multiple clones were sequenced to identify the clone coding wild type protein sequence. Sequence assembly and analysis were performed with SEQUENCHERTM 3.0 (Gene Codes Corporation, Ann Arbor, MI). Ambiguities and/or discrepancies between automated base calling in sequencing reads were visually examined and edited to the correct base call.
- nNR4 The final nucleotide sequence encoding nNR4 is shown as set forth in Figure 1A-B and as set forth as SEQ ID NO: 1 and the open reading frame for nNR4 results in a 357 amino add mouse nuclear receptor protein as shown in Figure 2A-B, Figure 3 and as also set forth in SEQ ID NO: 2.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- High Energy & Nuclear Physics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6814497P | 1997-12-12 | 1997-12-12 | |
US68144P | 1997-12-12 | ||
PCT/US1998/026446 WO1999029722A1 (en) | 1997-12-12 | 1998-12-11 | DNA MOLECULES ENCODING VERTEBRATE NUCLEAR RECEPTOR PROTEIN, nNR4 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1037912A1 true EP1037912A1 (en) | 2000-09-27 |
Family
ID=22080682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98963116A Withdrawn EP1037912A1 (en) | 1997-12-12 | 1998-12-11 | DNA MOLECULES ENCODING VERTEBRATE NUCLEAR RECEPTOR PROTEIN, nNR4 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1037912A1 (ja) |
JP (1) | JP2001525196A (ja) |
CA (1) | CA2315273A1 (ja) |
WO (1) | WO1999029722A1 (ja) |
-
1998
- 1998-12-11 CA CA002315273A patent/CA2315273A1/en not_active Abandoned
- 1998-12-11 JP JP2000524313A patent/JP2001525196A/ja not_active Withdrawn
- 1998-12-11 EP EP98963116A patent/EP1037912A1/en not_active Withdrawn
- 1998-12-11 WO PCT/US1998/026446 patent/WO1999029722A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9929722A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999029722A1 (en) | 1999-06-17 |
CA2315273A1 (en) | 1999-06-17 |
JP2001525196A (ja) | 2001-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060160140A1 (en) | Human nuclear receptor protein nNR7-1 | |
EP1017811A1 (en) | G-protein coupled glycoprotein hormone receptor hg38 | |
US6054295A (en) | DNA molecules encoding human nuclear receptor proteins | |
US7029865B2 (en) | DNA molecules encoding the melanocortin 4 receptor protein from rhesus monkey | |
EP1140968B1 (en) | Dna molecules encoding splice variants of the human melanocortin 1 receptor protein | |
WO1999010367A1 (en) | Dna molecules encoding human nuclear receptor proteins | |
CA2314434A1 (en) | Dna molecules encoding human nuclear receptor protein, nnr5 | |
WO1999029722A1 (en) | DNA MOLECULES ENCODING VERTEBRATE NUCLEAR RECEPTOR PROTEIN, nNR4 | |
US6645738B1 (en) | DNA molecules encoding the melanocortin 5 receptor protein from rhesus monkey | |
US7060463B2 (en) | DNA molecules encoding Macaca mulatta androgen receptor | |
US20030119100A1 (en) | DNA molecules encoding human nuclear receptor proteins | |
US7001742B1 (en) | Human uncoupling protein 3 | |
EP1133515A1 (en) | Dna molecules encoding hg51, a g-protein-coupled receptor | |
WO2000027862A1 (en) | Dna molecules encoding the melanocortin 3 receptor protein from rhesus monkey |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000712 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20030924 |